Clinical Trials

This phase one trial will study the monoclonal antibody BGB-A317 alongside Pamiparib.
More details

This study looks at anti-HER2 therapy plus endocrine therapy with or without palbociclib in patients with hormone receptor-positive HER2+ metastatic breast cancer. This study aims to extend the time before the disease progresses.
More details

The aim of the POSNOC trial is to find out if further axillary treatment is of benefit in women with macrometastases found in one or two lymph nodes.
More details

This randomised study compares radiation therapy with observation only, following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer.
More details

The purpose of this study is to assess the efficacy and safety of pembrolizumab (Keytruda) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
More details

This phase 2 clinical trial is looking into lymph node grafting for upper limb lymphoedema following breast cancer treatment.
More details

The New Zealand Familial Breast Cancer Study commenced in 2013 with the key goal of better-understanding DNA sequence changes in genes that alter the risk of developing breast cancer 
More details

The PantoCIN trial will test the ability of a cheap, widely available drug to prevent two of chemotherapy’s most unpleasant side-effects: delayed nausea and vomiting.
More details

A study assessing the safety and effectiveness of Q-122 for treating hot flushes, in women who have, or have had, breast cancer.
More details

THYmine2 is an observational study to assess whether the thymine loading test can prospectively categorize patients who cannot tolerate 5-FU treatment (e.g. FOLFOX, CapeOx, FLOX). This treatment is commonly used in breast cancer treatment. Reactions occur in approximately 10% of patients and can result in life-threatening events.
More details

A pilot trial investigating how different virtual reality experiences might improve well-being in advanced breast cancer patients.
More details

This study is evaluating the feasibility of accelerated partial breast irradiation (APBI) in women with breast cancer.
More details

A phase 3 study looking at the effectiveness of treatment with etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer who have stable brain metastases and have previously been treated with an Anthracycline, a Taxane, and Capecitabine.
More details

This is a proof-of-concept pilot study to determine if short-term treatment with denosumab (trade names Prolia and Xgeva) is a feasible chemoprevention option against breast cancer for BRCA1 and BRCA2 mutation carriers, as well as high risk, non-BRCA carriers.
More details

A phase II study evaluating the efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline-based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one-year total duration of Nivolumab.
More details

This is a phase 1 trial looking at CPI-444, a new drug that targets the adenosine-A2A receptor.
More details

You can join this phase 3 study if you've been diagnosed with early invasive breast cancer and you have had or will have, surgery for this, and you also plan to have chemotherapy as part of your anti-cancer treatment.
More details

This phase 1b study will determine the safety and efficacy of the combined treatment of Abraxane and phenelzine sulfate (Nardil) for metastatic or locally advanced breast cancer.
More details

The purpose of this study is to determine the safety and tolerability of INB03 in patients with metastatic cancer.
More details

This is a study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors.
More details

Lifepool is a research resource for study into breast cancer and women's health. It aims to recruit 100,000 Australian women. This will establish one of the largest cohorts in the world, providing research tools to answer critical questions about breast cancer. Lifepool aims to gather information on health and lifestyle, mammogram data and asks permission to track the health of each participant through linkage with other health databases.
More details

A phase 2 study of local therapy (stereotactic radiosurgery and/or surgery) for treatment of up to 5 brain metastases from HER2 positive breast cancer.
More details

This study is for women with ER+ breast cancer who want to interrupt endocrine therapy in order to become pregnant.
More details

An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer.
More details

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
More details

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
More details

The study is evaluating the impact of risk-reducing bilateral salpingo-oophorectomy (RRBSO) on sexual function, menopause symptoms and quality of life issues, bone health, cardiovascular health, sleep quality, depression/anxiety symptoms and cognitive function in high-risk, pre-menopausal women.
More details

The purpose of this study is to determine if breast cancer genetic material (known as circulating tumour DNA (ctDNA)) can be detected in the bloodstream. It is hoped that this research will demonstrate the utility of this circulating material as an early marker of breast cancer activity.​​
More details